Obesity Medicine

Latest News

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial / image credit ©Starmarpro/stock.adobe.com
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

January 17th 2025

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management / image credit ©brovarky/stock.adobe.com
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

January 15th 2025

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications
FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

January 8th 2025

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

December 20th 2024

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

December 20th 2024

More News

© 2025 MJH Life Sciences

All rights reserved.